Inflammatory Bowel Disease Affects the Outcome of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection
- PMID: 26905904
- PMCID: PMC5552196
- DOI: 10.1016/j.cgh.2016.02.018
Inflammatory Bowel Disease Affects the Outcome of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection
Abstract
Background & aims: A significant fraction of patients with recurrent Clostridium difficile infections (CDI) have inflammatory bowel disease (IBD). Fecal microbiota transplantation (FMT) can break the cycle of CDI recurrence and can be performed without evaluation of the colon. We evaluated the efficacy of colonoscopic FMT in patients with and without IBD, and whether we could identify IBD in patients during this procedure.
Methods: We collected clinical meta-data and colonoscopy results from 272 consecutive patients that underwent FMT for recurrent CDI at the University of Minnesota from 2008 through 2015. Patients had at least 2 spontaneous relapses of CDI following their initial episode and did not clear the infection after 1 extended antibiotic regimen. We collected random mucosal biopsies from patients' right colons to identify lymphocytic or collagenous colitis during the FMT procedure. Failure or success in clearing CDI was determined within or at 2 months after the FMT.
Results: Of patients undergoing FMT, 15% had established IBD and 2.6% were found to have IBD during the FMT procedure. A single colonoscopic FMT cleared CDI from 74.4% of patients with IBD and 92.1% of patients without IBD (P = .0018). Patients had similar responses to FMT regardless of immunosuppressive therapy. More than one-quarter of patients with IBD (25.6%) had a clinically significant flare of IBD after FMT. Lymphocytic colitis was documented in 7.4% of patients with endoscopically normal colon mucosa; only 3 of these patients (20%) required additional treatment for colitis after clearance of CDI.
Conclusions: Based on an analysis of 272 patients, FMT is somewhat less effective in clearing recurrent CDI from patients with IBD, compared with patients without IBD, regardless of immunosuppressive therapy. More than 25% of patients with IBD have a disease flare following FMT. Lymphocytic colitis did not affect the outcome of FMT, but a small fraction of these patients required pharmacologic treatment after the procedure.
Keywords: Clostridium Difficile; Complication; Crohn’s Disease; Ulcerative Colitis.
Copyright © 2016 AGA Institute. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
These authors disclose the following: Alexander Khoruts and Michael J. Sadowsky received research grant support from CIPAC Limited. Matthew J. Hamilton and Michael J. Sadowsky provided consulting services for CIPAC Limited. Byron P. Vaughn receives research salary support from Roche. The remaining authors disclose no conflicts.
Similar articles
-
Longitudinal microbiome analysis of single donor fecal microbiota transplantation in patients with recurrent Clostridium difficile infection and/or ulcerative colitis.PLoS One. 2018 Jan 31;13(1):e0190997. doi: 10.1371/journal.pone.0190997. eCollection 2018. PLoS One. 2018. PMID: 29385143 Free PMC article.
-
Microbial Engraftment and Efficacy of Fecal Microbiota Transplant for Clostridium Difficile in Patients With and Without Inflammatory Bowel Disease.Inflamm Bowel Dis. 2019 May 4;25(6):969-979. doi: 10.1093/ibd/izy398. Inflamm Bowel Dis. 2019. PMID: 30852592 Free PMC article.
-
Fecal Microbiota Transplantation is Safe and Efficacious for Recurrent or Refractory Clostridium difficile Infection in Patients with Inflammatory Bowel Disease.Inflamm Bowel Dis. 2016 Oct;22(10):2402-9. doi: 10.1097/MIB.0000000000000908. Inflamm Bowel Dis. 2016. PMID: 27580384
-
Fecal microbiota transplantation for the treatment of Clostridium difficile infection.J Hosp Med. 2016 Jan;11(1):56-61. doi: 10.1002/jhm.2449. Epub 2015 Sep 7. J Hosp Med. 2016. PMID: 26344412 Free PMC article. Review.
-
Fecal microbiota transplantation - methods of treatment of recurrent Clostridium difficile infections and other diseases.Postepy Hig Med Dosw (Online). 2017 Mar 27;71(0):220-226. doi: 10.5604/01.3001.0010.3807. Postepy Hig Med Dosw (Online). 2017. PMID: 28345530 Review.
Cited by
-
Long-Term Efficacy and Safety of Fecal Microbiota Transplantation for C. difficile Infections Across Academic and Private Clinical Settings.J Clin Gastroenterol. 2023 Nov-Dec 01;57(10):1024-1030. doi: 10.1097/MCG.0000000000001778. Epub 2022 Oct 14. J Clin Gastroenterol. 2023. PMID: 36227005 Free PMC article.
-
Gastrointestinal Microbiome - What We Need to Know in Clinical Practice.GE Port J Gastroenterol. 2020 Aug;27(5):336-351. doi: 10.1159/000505036. Epub 2020 Jan 14. GE Port J Gastroenterol. 2020. PMID: 32999906 Free PMC article. Review.
-
Short- and long-term follow-up after fecal microbiota transplantation as treatment for recurrent Clostridioides difficile infection in patients with inflammatory bowel disease.Therap Adv Gastroenterol. 2023 Mar 8;16:17562848231156285. doi: 10.1177/17562848231156285. eCollection 2023. Therap Adv Gastroenterol. 2023. PMID: 36910163 Free PMC article.
-
Gut Microbiota and Cancer: From Pathogenesis to Therapy.Cancers (Basel). 2019 Jan 3;11(1):38. doi: 10.3390/cancers11010038. Cancers (Basel). 2019. PMID: 30609850 Free PMC article. Review.
-
Scaling Safe Access to Fecal Microbiota Transplantation: Past, Present, and Future.Curr Gastroenterol Rep. 2018 Mar 28;20(4):14. doi: 10.1007/s11894-018-0619-8. Curr Gastroenterol Rep. 2018. PMID: 29594746 Review.
References
-
- Khoruts A, Sadowsky MJ, Hamilton MJ. Development of fecal microbiota transplantation suitable for mainstream medicine. Clin Gastroenterol Hepatol. 2015;13:246–250. - PubMed
-
- van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407–415. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources